[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Turn Therapeutics\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100620242","phase-2-a-double-blind-randomized-vehicle-controlled-phase-2-study-to-assess-the-efficacy-and-safety-of-gx-03-in-adult-subjects-with-moderate-to-severe-atopic-dermatitis-eczema-100620242",false,"NCT07355075","A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)","A Double-Blind, Vehicle-Controlled Study to Assess the Efficacy of GX-03 When Used in a Population of Adult Individuals With Moderate to Severe Eczema","GX-03 in AD","Participants must meet all of the following criteria:\n\n* Adults aged 18 to 80 years, inclusive\n* Male or female subjects in good general health as determined by medical history\n* Presence of visible eczematous skin with disease severity consistent with moderate to severe eczema, as assessed by:\n* Eczema Area and Severity Index (EASI) or Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™)\n* Ability to read, understand, and provide written informed consent in English\n* Willingness and ability to comply with study procedures, including study visits and daily topical application\n* Agreement to use only the assigned study product on designated areas of interest for the duration of the study\n\nExclusion Criteria\n\nIndividuals meeting any of the following criteria will be excluded:\n\n* Pregnant, breastfeeding, or planning pregnancy during the study\n* Presence of any skin condition or dermatologic disease that could interfere with study treatment or assessments\n* Use of systemic or topical immunosuppressive therapies, including corticosteroids, within 3 weeks prior to enrollment\n* Use of anti-inflammatory medications (e.g., topical steroids, ibuprofen, celecoxib); steroid nasal or ophthalmic drops are permitted\n* Use of topical medications at the test sites within 72 hours prior to enrollment\n* Damaged or altered skin at or near test sites (e.g., sunburn, tattoos, scars, uneven pigmentation) that could confound evaluations\n* Any medical condition that, in the investigator's judgment, places the subject at undue risk or compromises study integrity","ALL","18 Years","80 Years",{"count":21,"type":22},110,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This is a Phase 2, randomized, double-blind, vehicle-controlled clinical study evaluating the efficacy and safety of GX-03 topical ointment in adult subjects with moderate to severe atopic dermatitis (eczema). The study plans to enroll up to 120 eligible patients with a target of at least 100 completing the study and an ability to expand enrollment up to 200 subjects based on a pre-specified interim assessment conducted by an Independent Data Monitoring Committee (IDMC). Subjects will be randomized in a 1:1 ratio to receive either GX-03 or vehicle control for 8 weeks.\n\nThe study is designed to evaluate improvement in investigator-assessed disease severity, itch, and patient-reported eczema symptoms following topical treatment with GX-03 compared with vehicle control. Efficacy assessments include the Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™), Eczema Area and Severity Index (EASI), Peak Pruritus Numeric Rating Scale (PP-NRS), and Patient-Oriented Eczema Measure (POEM).\n\nAn interim assessment of conditional power for the primary efficacy endpoint will occur after the first 50 subjects complete the Week 8 visit or withdraw prematurely. Based on pre-specified criteria defined in the IDMC Charter, the IDMC may recommend continuation as planned, expansion of enrollment up to 200 subjects, or early curtailment of enrollment.",[28,29,30],"Eczema Atopic Dermatitis","Eczema","Atopic Dermatitis",[32,33,29,30],"Moderate-Severe AD","Moderate-Severe Eczema","RECRUITING","2026-05-13",{"date":37,"type":38},"2026-05-18","ACTUAL",{"date":40,"type":38},"2025-07-11",{"date":42,"type":22},"2026-07-10",{"name":44,"class":45},"Turn Therapeutics","INDUSTRY",""]